Biomarin Pharmaceutical

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Established: 1997-01-01

Employees: -

Market Cap: $17.2B

Website: http://www.biomarin.com

Clinical Trials

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Phase 1

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: PRO045, 0.15 mg/kg/week
Drug: PRO045, 6.0 mg/kg/week
Drug: PRO045, 1.0 mg/kg/week
Drug: PRO045, 3.0 mg/kg/week
Drug: PRO045, 9.0 mg/kg/week
Drug: PRO045, selected dose

First Posted Date: 2013-04-08

Last Posted Date: 2017-12-08

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 15

Registration Number: NCT01826474

Locations: 🇮🇹
Policlinico Universitario Agostino Gemelli, Roma, Italy
🇫🇷
Institut de Myologie, Paris, France
🇬🇧
Great Ormond Street Hospital for Children, London, United Kingdom

and more 3 locations

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

Phase 3

Completed

Conditions: Phenylketonuria

Interventions: Drug: BMN 165

First Posted Date: 2013-03-28

Last Posted Date: 2019-02-26

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 261

Registration Number: NCT01819727

Locations: 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Albany Medical College, Albany, New York, United States

and more 28 locations

A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects

Phase 3

Terminated

Conditions: Muscular Dystrophies

Interventions: Drug: Drisapersen

First Posted Date: 2013-03-04

Last Posted Date: 2018-06-14

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 53

Registration Number: NCT01803412

Locations: 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States

and more 10 locations

A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Other: Observational study

First Posted Date: 2012-12-20

Last Posted Date: 2017-12-08

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 269

Registration Number: NCT01753804

Locations: 🇦🇷
Hospital de Pediatria Prof Dr Juan P Garrahan, Buenos Aires, Argentina
🇺🇸
UC Davis Health System, Sacramento, California, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 13 locations

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Phase 2

Terminated

Conditions: Mucopolysaccharidosis IVA
Morquio A Syndrome
MPS IVA

Interventions: Drug: BMN 110

First Posted Date: 2012-10-02

Last Posted Date: 2016-01-12

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 16

Registration Number: NCT01697319

Locations: 🇬🇧
NIHR/Wellcome Trust Birmingham CRF, Queen Elizabeth Hospital, Birmingham, United Kingdom
🇩🇪
Universitätsklinikum Hamburg, Hamburg, Germany
🇬🇧
Salford Royal NHS Foundation Trust, Salford, United Kingdom

and more 4 locations

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Phase 2

Terminated

Conditions: Mucopolysaccharidosis IVA
Morquio A Syndrome
MPS IVA

Interventions: Drug: BMN 110

First Posted Date: 2012-05-31

Last Posted Date: 2016-02-01

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 25

Registration Number: NCT01609062

A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia

Completed

Conditions: Achondroplasia

First Posted Date: 2012-05-22

Last Posted Date: 2021-04-13

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 363

Registration Number: NCT01603095

Locations: 🇺🇸
Children's Hospital and Research Center Oakland, Oakland, California, United States
🇦🇺
Murdoch Children's Research Institute, Parkville, Victoria, Australia
🇦🇺
The Children's Hospital at Westmead, Westmead, Australia

and more 17 locations

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

Phase 1

Completed

Conditions: Achondroplasia

Interventions: Drug: Normal Saline
Drug: BMN 111

First Posted Date: 2012-05-03

Last Posted Date: 2012-06-11

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 74

Registration Number: NCT01590446

Locations: 🇺🇸
Covance CRU Inc., Evansville, Indiana, United States

A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

Phase 2

Completed

Conditions: Phenylketonuria

Interventions: Biological: BMN 165 (rAvPAL-PEG)

First Posted Date: 2012-03-22

Last Posted Date: 2019-08-06

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01560286

Locations: 🇺🇸
Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
The Children's Hospital, Aurora, Colorado, United States
🇺🇸
University of Florida, Gainesville, Gainesville, Florida, United States

and more 3 locations

Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Phase 2

Completed

Conditions: Morquio A Syndrome
MPS IVA
Mucopolysaccharidosis IVA

Interventions: Drug: BMN 110

First Posted Date: 2012-01-24

Last Posted Date: 2017-08-10

Lead Sponsor: BioMarin Pharmaceutical

Target Recruit Count: 15

Registration Number: NCT01515956

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy